Itraconazole

[1]  L. Martínez-Chavarría,et al.  Chromoblastomycosis caused by Fonsecaea monophora in Mexico. , 2021, Journal de mycologie medicale.

[2]  Itraconazole , 2020, Reactions Weekly.

[3]  Aditya K. Gupta.  Pharmacoeconomic Analysis of Oral Antifungal Therapies Used to Treat Dermatophyte Onychomycosis of the Toenails , 1998, PharmacoEconomics.

[4]  J. Arrese,et al.  Treatment and Prophylaxis of Tinea Infections , 1996, Drugs.

[5]  S. Bahadır,et al.  Continuous terbinafine or pulse itraconazole: a comparative study on onychomycosis , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  F. Raffi,et al.  Itraconazole oral solution for treatment of fluconazole resistant oral/esophageal candidosis in HIV-infected patients : Results of a prospective multicenter study. I. Clinical assessment , 2008 .

[7]  J. Arrese,et al.  Facing up to the diagnostic uncertainty and management of onychomycoses , 1999, International journal of dermatology.

[8]  C. Leutner,et al.  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole , 1999, Mycoses.

[9]  R. Li,et al.  Therapeutic Efficacy and Safety of One-Week Intermittent Therapy with Itraconazole for Onychomycosis in a Chinese Patient Population , 1999, Dermatology.

[10]  N. Shear,et al.  The new oral antifungal agents for onychomycosis of the toenails , 1999, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  B. Sigurgeirsson,et al.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .

[12]  A. Favero,et al.  Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  P. Doncker,et al.  Reduction in the growth of non‐dermatophyte moulds by itraconazole: evaluation by corneofungimetry assay: Beeinträchtigung des Wachstums von Nicht‐Dermatophyten‐Schimmeln durch Itraconazol: Bewertung mittels korneofungimetrischer Methode , 1998, Mycoses.

[14]  A. Stary.  Treatment of vaginal candidosis , 1998 .

[15]  R. Ramphal.  1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever , 1998 .

[16]  C. Leutner,et al.  Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia , 1998, Leukemia.

[17]  Honghui Zhou,et al.  A Pharmacokinetic Study of Intravenous Itraconazole Followed by Oral Administration of Itraconazole Capsules in Patients with Advanced Human Immunodeficiency Virus Infection , 1998, Journal of clinical pharmacology.

[18]  J. Barone,et al.  Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers , 1998, Antimicrobial Agents and Chemotherapy.

[19]  G. Stingl,et al.  A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Groen,et al.  Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis , 1998, Clinical and experimental dermatology.

[21]  R. Soutar,et al.  Severe vincristine toxicity in combination with itraconazole. , 1998, Clinical and laboratory haematology.

[22]  J. Ring,et al.  Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. , 1998, Mycoses (Berlin).

[23]  W. Liao,et al.  Small‐dose itraconazole pulse therapy in the treatment of onychomycosis , 1997, Mycoses.

[24]  J. Meis,et al.  Progress in fighting systemic fungal infections in haematological neoplasia , 1997, Supportive Care in Cancer.

[25]  J. Decruyenaere,et al.  Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units , 1997, Antimicrobial agents and chemotherapy.

[26]  L. Laine,et al.  A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. , 1997, The Journal of infectious diseases.

[27]  S. Koletar,et al.  Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. , 1997, Clinical therapeutics.

[28]  H. Degreef,et al.  Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. , 1997, Journal of the American Academy of Dermatology.

[29]  C. R. Daniel,et al.  A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. , 1997, Journal of the American Academy of Dermatology.

[30]  T. Rantanen,et al.  A double‐blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe–nail onychomycosis , 1997, The British journal of dermatology.

[31]  H. Degreef,et al.  Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. , 1997, Journal of the American Academy of Dermatology.

[32]  A. Bonifaz,et al.  Itraconazole in onychomycosis: intermittent dose schedule , 1997, International journal of dermatology.

[33]  C. Kibbler.  Empirical antifungal therapy in febrile neutropenic patients: current status. , 1997, Current topics in medical mycology.

[34]  C. Kauffman.  Itraconazole oral solution: clinical review and experience. , 1997, AIDS Patients Care and STDs.

[35]  Claude Carbón,et al.  Uveitis Associated with Rifabutin Prophylaxis and Itraconazole Therapy , 1996, Annals of Internal Medicine.

[36]  B. Elewski,et al.  Nondermatophyte causes of onychomycosis and superficial mycoses. , 1996, Current topics in medical mycology.

[37]  L. de Repentigny,et al.  Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. , 1996, Chemotherapy.

[38]  J. Heykants,et al.  Effect of Food on the Pharmacokinetics of a New Hydroxypropyl‐β‐Cyclodextrin Formulation of Itraconazole , 1996, Pharmacotherapy.

[39]  B. Piraccini,et al.  Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. , 1996, Journal of the American Academy of Dermatology.

[40]  J. Arrese,et al.  Present and potential diagnostic techniques in onychomycosis. , 1996, Journal of the American Academy of Dermatology.

[41]  R. Hay,et al.  The use of itraconazole in onychomycosis , 1996 .

[42]  W. Caras,et al.  Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. , 1996, Mayo Clinic proceedings.

[43]  E. van Doorslaer,et al.  Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. , 1996, Dermatology.

[44]  E. Helm,et al.  [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis]. , 1996, Mycoses.

[45]  K. de Beule,et al.  Itraconazole: pharmacology, clinical experience and future development. , 1996, International journal of antimicrobial agents.

[46]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[47]  P. Jacqmin,et al.  Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. , 1995, Annales de la Societe belge de medecine tropicale.

[48]  D. Greer.  EVOLVING ROLE OF NONDERMATOPHYTES IN ONYCHOMYCOSIS , 1995, International journal of dermatology.

[49]  P. Neuvonen,et al.  Itraconazole interacts with felodipine. , 1995, Journal of the American Academy of Dermatology.

[50]  J. Arrese,et al.  Fungi in onychomycosis. A study by immunohistochemistry and dual flow cytometry , 1995 .

[51]  F. Hecht,et al.  Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. , 1995, The American journal of medicine.

[52]  C. Piérard‐franchimont,et al.  Fungal cultures on cyanoacrylate skin surface strippings as a dose-finding method for topical antifungals. A placebo-controlled study with 0.25% and 0.50% itraconazole cream. , 1995, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[53]  G. Piérard,et al.  Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. , 1995, Journal of the American Academy of Dermatology.

[54]  S. Higgins,et al.  Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. , 1995, The British journal of clinical practice.

[55]  M. Cuétara,et al.  ITRACONAZOLE VERSUS GRISEOFULVIN IN THE TREATMENT OF TINEA CAPITIS: A DOUBLE‐BLIND RANDOMIZED STUDY IN CHILDREN , 1994, International journal of dermatology.

[56]  R. Pariser,et al.  Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. , 1994, Journal of the American Academy of Dermatology.

[57]  J. Perfect,et al.  NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. , 1994, The American journal of medicine.

[58]  B. Elewski.  Tinea capitis: itraconazole in Trichophyton tonsurans infection. , 1994, Journal of the American Academy of Dermatology.

[59]  A. Tunkel,et al.  Itraconazole: A New Triazole Antifungal Agent , 1994, Infection Control & Hospital Epidemiology.

[60]  D. Le Ray,et al.  TREATMENT OF CUTANEOUS LEISHMANIASIS WITH ORAL ITRACONAZOLE , 1994, International journal of dermatology.

[61]  M. Rinaldi,et al.  Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  M. Heenen,et al.  Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. , 1994, Dermatology.

[63]  S. Im,et al.  Itraconazole‐induced acute hepatitis , 1993, The British journal of dermatology.

[64]  H. Shih,et al.  Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. , 1993, The American journal of medicine.

[65]  D. Stevens,et al.  Treatment of sporotrichosis with itraconazole , 1993 .

[66]  D. Rigopoulos,et al.  Itraconazole in the treatment of tinea corporis and tinea cruris , 1993, Clinical and experimental dermatology.

[67]  W. Meinhof.  Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. , 1993, Journal of the American Academy of Dermatology.

[68]  J. Graybill,et al.  Itraconazole-didanosine excipient interaction. , 1993, JAMA.

[69]  P J Green,et al.  Interaction of itraconazole and digoxin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  G. Stein,et al.  Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis , 1993, Antimicrobial Agents and Chemotherapy.

[71]  G. Piérard,et al.  Comparative study of the activity and lingering effect of topical antifungals. , 1993, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[72]  S. Goldberg,et al.  Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  K. Kohtamäki,et al.  A Double-Blind Comparison of the Effectiveness of Itraconazole Oral Capsules with Econazole Vaginal Capsules in the Treatment of Vaginal Candidosis , 1992 .

[74]  M. Saag,et al.  Itraconazole therapy for blastomycosis and histoplasmosis , 1992 .

[75]  J. Pether,et al.  Acute pyogenic Pseudallescheria boydii foot infection sequentially treated with miconazole and itraconazole. , 1992, The Journal of infection.

[76]  A. Lavrijsen,et al.  Hepatic injury associated with itraconazole , 1992, The Lancet.

[77]  J. V. van Cutsem,et al.  Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. , 1992, Journal of the American Academy of Dermatology.

[78]  D. Denning,et al.  US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. , 1992, Chemotherapy.

[79]  L. Sobral,et al.  Itraconazole versus placebo in the management of vaginal candidiasis , 1991, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[80]  M. Diaz,et al.  Itraconazole in the treatment of coccidioidomycosis. , 1991, Chest.

[81]  J. Dunn,et al.  High-dose itraconazole in the treatment of severe mycoses , 1991, Antimicrobial Agents and Chemotherapy.

[82]  J. Shenep,et al.  Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1991, The Journal of infectious diseases.

[83]  D. Denning,et al.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. , 1990, Reviews of infectious diseases.

[84]  R. M. Tucker,et al.  Adverse events associated with itraconazole in 189 patients on chronic therapy. , 1990, The Journal of antimicrobial chemotherapy.

[85]  G. Cauwenbergh,et al.  Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. , 1990, British journal of clinical practice. Supplement.

[86]  E. Difonzo,et al.  Itraconazole in dermatophyte infections: clinical experience in Italy. , 1990, British journal of clinical practice. Supplement.

[87]  R. Legendre,et al.  Itraconazole in the treatment of tinea capitis. , 1990, Journal of the American Academy of Dermatology.

[88]  M. Kramer,et al.  Cyclosporine and itraconazole interaction in heart and lung transplant recipients. , 1990, Annals of internal medicine.

[89]  J. V. van Cutsem,et al.  Itraconazole in the treatment of superficial mycoses—a double‐blind study vs. placebo , 1990, Clinical and experimental dermatology.

[90]  R. M. Tucker,et al.  Itraconazole therapy for chronic coccidioidal meningitis. , 1990, Annals of internal medicine.

[91]  A. Polak.  Mode of Action Studies , 1990 .

[92]  Á. Restrepo,et al.  Treatment of paracoccidioidomycosis with itraconazole. , 1990, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[93]  R. C. Summerbell,et al.  Onychomycosis, Tinea Pedis and Tinea Manuum Caused by Non‐Dermatophytic Filamentous Fungi Nicht‐Dermatophyten‐Fadenpilze als Erreger von Onychomykosen, Tinea pedis und Tinea manuum , 1989, Mycoses.

[94]  R. Woestenborghs,et al.  The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.

[95]  G. Piérard,et al.  Culture of fungi on cyanoacrylate skin surface strippings‐a quantitative bioassay for evaluating antifungal drugs , 1989, Clinical and experimental dermatology.

[96]  G. Verhoef,et al.  Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels , 1989, Mycoses.

[97]  R. M. Tucker,et al.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis. , 1989, Archives of internal medicine.

[98]  R. Negroni,et al.  Itraconazole in human histoplasmosis. , 1989, Mycoses (Berlin).

[99]  J. V. van Cutsem.  The in-vitro antifungal spectrum of itraconazole. , 1989, Mycoses.

[100]  J. V. van Cutsem.  Oral, topical and parenteral antifungal treatment with itraconazole in normal and in immunocompromised animals. , 1989, Mycoses (Berlin).

[101]  Á. Restrepo,et al.  Treatment of Chromoblastomycosis with Itraconazole , 1988, Annals of the New York Academy of Sciences.

[102]  R. M. Tucker,et al.  Treatment of Mycoses with Itraconazole , 1988, Annals of the New York Academy of Sciences.

[103]  K. Beule,et al.  The Treatment of Aspergillosis and Aspergilloma with Itraconazole, Clinical Results of an Open International Study (1982 ‐ 1987)/Die Behandlung der Aspergillose und des Aspergilloms mit Itraconazol, Klinische Ergebnisse einer offenen internationalen Studie (1982 ‐ 1987) , 1988, Mycoses.

[104]  H. Degreef,et al.  Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.

[105]  H. Degreef,et al.  Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. , 1987, Reviews of infectious diseases.

[106]  A. Raimondi,et al.  Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment. , 1987, Reviews of infectious diseases.

[107]  D. Borelli.  A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. , 1987, Reviews of infectious diseases.

[108]  Á. Restrepo,et al.  Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. , 1986, Archives of dermatology.

[109]  D. K. Andriasian.  [Treatment of onychomycosis]. , 1950, Vestnik venerologii i dermatologii.